Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

bFGF rescues dysfunctional properties of adipose-derived stem cells from individuals with type 2 diabetes by modulating their miRNA profile.

Civit-Urgell A., Peña E., Bejar MT., Moscatiello F., Vilahur G., Badimon L.

Animal Study on Type 2 Diabetes, Chronic Wound, published in Diabetologia (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Diabetologia (2025)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
40905998
PMCID
PMC12594652
DOI
10.1007/s00125-025-06533-0
Citations
3

Abstract (original English)

Aims/hypothesis The aim of this study was to investigate whether basic fibroblast growth factor (bFGF) can restore the proliferation and migration capacities of adipose-derived stem cells (ASCs), which are impaired by type 2 diabetes, and improve vascular remodelling. Methods ASCs obtained from individuals with or without diabetes were cultured with 10 ng/ml bFGF for 9 days. The ASCs were phenotypically characterised and functionally tested for proliferation capacity. Differentially expressed miRNAs before and after treatment were analysed using miRNA arrays. Crosstalk between ASCs and human vascular smooth muscle cells (HVSMCs) was assessed using wound healing, transwell migration and co-culture assays. Finally, a Matrigel plug assay in nude mice was used to evaluate the contribution of ASCs to neovessel formation. Results bFGF treatment significantly enhanced the proliferation and migration of ASCs from individuals with type 2 diabetes (T2DM ASCs), and altered the expression of miRNAs associated with ASC proliferation. ASCs promoted HVSMC migration and, when co-cultured, facilitated tube-like structure formation. In vivo Matrigel plug assays revealed that bFGF treatment enhanced neovessel formation. Although both non-T2DM ASCs (ASCs from individuals without type 2 diabetes) and untreated T2DM ASCs stimulated angiogenesis, bFGF-treated subcutaneous and visceral T2DM ASCs promo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansDiabetes Mellitus, Type 2MicroRNAsFibroblast Growth Factor 2AnimalsCell ProliferationCell MovementMiceStem CellsAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research